Ikena Oncology, Inc.

NASDAQ:IKNA

1.51 (USD) • At close January 14, 2025
Bedrijfsnaam Ikena Oncology, Inc.
Symbool IKNA
Munteenheid USD
Prijs 1.51
Beurswaarde 60,790,184
Dividendpercentage 0%
52-weken bereik 1.22 - 1.94
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mark Manfredi Ph.D.
Website https://ikenaoncology.com

An error occurred while fetching data.

Over Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing

Vergelijkbare Aandelen

IO Biotech, Inc. logo

IO Biotech, Inc.

IOBT

0.829 USD

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

0.797 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.692 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

1.26 USD

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

3.56 USD

Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

0.757 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

0.606 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)